28 August 2020 - - US-based Target RWE, an evidence solutions company for the pharmaceutical and biotech industries, has built a COVID-19 data set of more than 70,000 patients to support global research and healthcare partners as they respond to the coronavirus pandemic, the company said.

The initial characteristics and outcomes from the data set have been published in the peer-reviewed journal Clinical Infectious Diseases.

Target RWE has quickly accumulated deidentified real-time data from hospitals across all geographic regions of the United States. With more than 70,000 patients, Target RWE's COVID-19 data set will continue to grow to support and provide valuable information to healthcare partners.

In parallel, Target RWE has completed an initial analysis on its COVID-19 data set of characteristics and outcomes.

The data published in Clinical Infectious Diseases captured more than 11,000 COVID-19 patients at 245 hospitals across 38 states in the country.

The most common comorbidities among hospitalized patients included hypertension (46.7%), diabetes (27.8%), cardiovascular disease (18.6%), obesity (16.1%), and chronic kidney disease (12.2%).

Mortality among hospitalized patients was 21.4% and increased to 70.5% among those on mechanical ventilation.

Older age, male sex, preexisting chronic kidney disease, and cardiovascular disease were independently associated with worse outcomes.

Over 4,000 patients had been treated with hydroxychloroquine and remdesivir was starting to be utilized to treat hospitalized patients.

Other hospital data, including coding and billing, will be incorporated to provide a comprehensive view of the COVID-19 patient journey, including outcomes.

These data can greatly facilitate COVID-19 treatment and prevention research currently underway by informing protocol design or acting as a control arm in situations where there are no other means to do so.

Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.

Target RWE designs custom data sets, analyses, and evidence to address the complexities of healthcare evidence questions and quality initiatives.

Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data from a large network of participating sites (academic and community) across the United States, Europe, and other non-US locations.

Target RWE's data sets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases.